Document is current

Article History

Received: 10 October 2022

Accepted: 11 December 2023

First Online: 29 January 2024

Declarations

:

: In accordance with the U.S. Common Rule and after Institutional Review Board (IRB) approval, all human subject tissue collection was carried out with institutional review board (IRB) approval (Dana Farber/Harvard Cancer Center protocol 13–416 and Partners protocol 2017P000635/PHS). Informed consent was obtained from all participants prior to enrolment. The research adhered to the declaration of Helsinki.

: Not applicable.

: P.V.K serves on the Scientific Advisory Board to Celsius Therapeutics, Inc., and Biomage Inc. D.B.S. is a co-founder and holds equity in Clear Creek Bio and is a consultant and holds equity in SAFI Biosolutions. D.T.S. is a founder, director, and stockholder of Magenta Therapeutics, Clear Creek Bio, and LifeVaultBio. He is a director and stockholder of Agios Pharmaceuticals and Editas Medicines and a founder and stockholder of Fate Therapeutics and Geruda Therapeutics. He is a consultant for FOG Pharma, Inzen Therapeutics, ResoluteBio, and VCanBio and receives sponsored research support on an unrelated project from Sumitomo Dianippon. D.B.S. is a founder, consultant, and shareholder for Clear Creek Bio. The remaining authors declare that they do not have any competing interests.